- Stocks
- Healthcare
- NASDAQ: RPRX

Price (delayed)

$43.96

Market cap

$17.06B

P/E Ratio

33.3

Dividend/share

$0.47

EPS

$1.32

Enterprise value

$21.87B

Royalty Pharma's gross profit has increased by 17% YoY and by 6% from the previous quarter

The revenue has increased by 17% YoY and by 6% from the previous quarter

RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter

The net income has plunged by 58% YoY and by 56% from the previous quarter

The company's quick ratio fell by 17% QoQ

What are the main financial stats of RPRX

Market
Valuations
Earnings

Shares outstanding

388.13M

Market cap

$17.06B

Enterprise value

$21.87B

Price to earnings (P/E)

33.3

Price to book (P/B)

3.54

Price to sales (P/S)

7.78

EV/EBIT

19.32

EV/EBITDA

19.32

EV/Sales

10.3

Revenue

$2.12B

EBIT

$1.13B

EBITDA

$1.13B

Free cash flow

$2.03B

Per share
Balance sheet
Liquidity

EPS

$1.32

Free cash flow per share

$5.42

Book value per share

$12.42

Revenue per share

$5.65

TBVPS

$42.59

Total assets

$16.02B

Total liabilities

$6.12B

Debt

$5.82B

Equity

$4.82B

Working capital

$2.39B

Debt to equity

1.21

Current ratio

8.76

Quick ratio

6.82

Net debt/EBITDA

4.25

Margins
Efficiency
Dividend

EBITDA margin

53.3%

Gross margin

100%

Net margin

45.9%

Operating margin

75.2%

Return on assets

6.4%

Return on equity

21%

Return on invested capital

5.9%

Return on capital employed

7.2%

Return on sales

53.3%

Dividend yield

1.09%

DPS

$0.47

Payout ratio

35.5%

How has the Royalty Pharma stock price performed over time

Intraday

1.74%

1 week

4.99%

1 month

0.34%

1 year

N/A

YTD

-12.17%

QTD

0.78%

How have Royalty Pharma's revenue and profit performed over time

Revenue

$2.12B

Gross profit

$2.12B

Operating income

$1.6B

Net income

$975.04M

Gross margin

100%

Net margin

45.9%

Royalty Pharma's net margin has shrunk by 65% YoY and by 59% QoQ

The net income has plunged by 58% YoY and by 56% from the previous quarter

The operating margin has declined by 48% year-on-year and by 42% since the previous quarter

The operating income has contracted by 39% YoY and by 39% from the previous quarter

What is Royalty Pharma's growth rate over time

What is Royalty Pharma stock price valuation

P/E

33.3

P/B

3.54

P/S

7.78

EV/EBIT

19.32

EV/EBITDA

19.32

EV/Sales

10.3

RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter

The revenue has increased by 17% YoY and by 6% from the previous quarter

How efficient is Royalty Pharma business performance

The ROA has plunged by 68% YoY and by 59% from the previous quarter

Royalty Pharma's return on sales has shrunk by 63% YoY and by 56% QoQ

The ROIC has shrunk by 62% YoY and by 54% QoQ

RPRX's ROE has plunged by 53% from the previous quarter and by 53% YoY

What is RPRX's dividend

DPS

$0.47

Dividend yield

1.09%

Payout ratio

35.5%

How did Royalty Pharma financials performed over time

Royalty Pharma's total assets is 162% more than its total liabilities

Royalty Pharma's total assets has increased by 29% YoY

The company's quick ratio fell by 17% QoQ

Royalty Pharma's debt is 21% higher than its equity

RPRX's equity is down by 21% year-on-year but it is up by 8% since the previous quarter

The debt to equity has increased by 19% YoY but it has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.